Skip to content
CEOSalary.comExecutive Compensation Benchmarking

Pharmaceuticals & Biotechnology

Yarrow Bioscience, Inc. CEO pay

David Domzalski, President and Chief Executive Officer. Fiscal year 2024, as reported to the SEC.

Total compensation

$2M

$1,973,607 for fiscal 2024: the Summary Compensation Table total, with stock and option awards at their grant-date value.

Definitive proxy statement, filed 2025-11-12SEC accession number 0001104659-25-110346

In context

The median chief executive among 248 Pharmaceuticals & Biotechnology companies with under $100M in revenue was paid $1.6M. The middle half ranged from $694K to $3.3M.

David Domzalski's total is above that median.

See how your pay compares to Yarrow Bioscience, Inc.'s peers

CEOSalary breaks this total into salary, bonus, stock and option awards, builds a peer set of comparable companies around it, and places your own package against them, with every figure cited to its filing.

Start a 3-day trial

Source: Yarrow Bioscience, Inc.'s definitive proxy statement (SEC Form DEF 14A), Summary Compensation Table, fiscal year 2024. Figures are as reported by the company and are not adjusted or estimated. Context figures are from CEOSalary's snapshot of SEC filings as of 2026-10-28. Not financial, legal or compensation-consulting advice.

We use analytics cookies to understand how the site is used. Nothing is loaded until you choose. Read our Cookie Policy